Omeros Hits New 1-Year High at $14.97 (OMER)
Omeros (NASDAQ:OMER) shares reached a new 52-week high on Tuesday , StockRatingsNetwork.com reports. The company traded as high as $14.97 and last traded at $14.92, with a volume of 390,120 shares changing hands. The stock had previously closed at $14.01.
Several analysts have recently commented on the stock. Analysts at Needham & Company LLC reiterated a “buy” rating on shares of Omeros in a research note on Monday, April 7th. They now have a $17.00 price target on the stock, up previously from $15.00. Separately, analysts at WBB Securities raised their price target on shares of Omeros from $20.00 to $30.00 in a research note on Monday, April 7th. They now have a “strong-buy” rating on the stock.
The stock has a 50-day moving average of $11.77 and a 200-day moving average of $11.41. The company’s market cap is $523.9 million.
Omeros (NASDAQ:OMER) last announced its earnings results on Monday, May 12th. The company reported ($0.45) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.45). The company had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.45 million. During the same quarter in the prior year, the company posted ($0.40) earnings per share. The company’s quarterly revenue was down 90.9% on a year-over-year basis. Analysts expect that Omeros will post $-1.55 EPS for the current fiscal year.
In other Omeros news, Director Thomas J. Cable sold 5,000 shares of Omeros stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $11.80, for a total value of $59,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Omeros Corporation operates as a biopharmaceutical company focused on the discovery, development and commercialization of products focused on inflammation and disorders of the central nervous system.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.